Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L, Shao W, Zhou C, Yang H, Yang L, Cai Q, Wang J, Shi Y, Huang L, Zhang J.
Guo L, et al. Among authors: yang l, yang h.
Mol Med. 2023 Oct 6;29(1):134. doi: 10.1186/s10020-023-00736-0.
Mol Med. 2023.
PMID: 37803271
Free PMC article.
Review.